June 30, 2024
Headlines

Medicine

NeOnc Technologies Secures $18.5 Million to Propel Breakthrough Brain Cancer Therapies Through Phase II Trials

Editor05 mins

NeOnc Technologies Holdings, Inc., a forefront player in clinical-stage biotechnology, has successfully concluded an $18.5 million financing round aimed at advancing its innovative approach to treating brain cancer. This funding milestone includes new equity investment and debt conversions, reflecting a substantial increase in NeOnc’s valuation and reinforcing its commitment to pioneering neurological therapeutics. The financing…

Read More

DiaMedica Therapeutics Secures $11.8 Million Investment to Advance Breakthrough Treatments

Editor04 mins

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a pioneering biopharmaceutical firm renowned for its innovative approach to severe ischemic diseases, has announced a significant milestone today. The company successfully finalized agreements for a private placement offering, securing $11.8 million in gross proceeds from accredited investors. This strategic funding round underscores DiaMedica’s commitment to advancing clinical and product…

Read More

Formation Bio Secures $372 Million Series D Funding to Propel AI-Driven Drug Development

Editor07 mins

Formation Bio, a pioneering force at the intersection of technology and pharmaceuticals, has announced a landmark achievement with the closure of a $372 million Series D financing round. This funding round was led by prominent investors including a16z and Sanofi, with continued support from existing backers such as Sequoia, Thrive, Emerson Collective, and Lachy Groom,…

Read More

UroMems Raises $47 Million in Series C Funding to Advance Groundbreaking Treatment for Stress Urinary Incontinence

Editor05 mins

UroMems, a pioneering global company specializing in mechatronics technology for treating stress urinary incontinence (SUI), has secured $47 million in its Series C financing round, marking a record fundraising achievement for the company. This capital infusion will propel pivotal clinical trials of their groundbreaking UroActive™ System, the world’s first smart automated artificial urinary sphincter (AUS)…

Read More
Stacey Pugh, CEO of Endogenex

Endogenex Secures $88 Million in Series C Funding to Advance Breakthrough Diabetes Treatment

Editor04 mins

Endogenex, a pioneering clinical-stage medical device company dedicated to transforming diabetes care, has successfully closed an oversubscribed Series C financing round, raising a remarkable $88 million. This substantial funding boost will propel the company towards completing its pivotal ReCET Clinical Study, a critical step in bringing their innovative ReCET™ System to market for patients suffering…

Read More

Vico Therapeutics Secures €65.8 Million in Series B Funding to Advance Groundbreaking Neurological Therapies

Editor04 mins

Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases. Vico Therapeutics specializes in antisense oligonucleotide…

Read More